Timothy L. MacDonald

SphynKx Therapeutics LLC engages in developing, discovering and commercializing novel therapies for the treatment of fibrosis. Its Sphingosine 1-phosphate (S1P) is recognized as a key regulator of many of the cellular processes that promote wound healing and fibrogenesis, which include fibroblast and immune cell migration, vascular leak, proliferation, angiogenesis, and TGF-ß signaling. The company was founded by Andrew Bolt, Kevin R. Lynch, Webster Santos and Timothy L. Macdonald in 2010 and is headquartered in Charlottesville, VA.

Catena Pharmaceuticals, Inc. is focused on the development and commercialization of novel GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's proprietary chemistry is uniquely capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states. Catena focuses its research and product development efforts around manipulation of the biology of the blood-borne signaling molecule lysophosphatidic acid (LPA). Its products will either block the signaling of LPA, or reduce production of LPA, or mimic LPA. The company was founded by Kevin Lynch and Tim MacDonald in the year 2008 and is headquartered in Durham, NC.

Limulus Management Co. LLC is a venture capital firm founded by Lawrence Miller and Paul Howard in 1999. It is headquartered in Newton, Massachusetts.

Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA.

Adenosine Therapeutics LLC manufactures and develops pharmaceutical products. It provides drugs for sepsis, heart attack, vascular injury, asthma, spinal cord injury and organ transplantation. The company was founded by Joel M. Linden, George A. Beller and Robert S. Capon in 1999 and is headquartered in Charlottesville, VA.